← Back to patent-cliff list
Elzovantinib
Tier C — Watch / tradeElzovantinib
Turning Point Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CSF1R, c-Met, SRC
Indications (approved)：Non-small cell lung cancer, Solid tumour, Gastric cancer
Regional status
US
Phase I
2019-09-05
EU
Phase I
2019-09-05
China
Phase II
2022-05-27
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Elzovantinib?
Approved indications include: Non-small cell lung cancer, Solid tumour, Gastric cancer.
When does the Elzovantinib patent expire?
No public expiry year is available for Elzovantinib yet; this page updates once verified.
How do I get a quote for Elzovantinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05